# Discovery of Sirolimus Sensitive Biomarkers in Blood

> **NCT03304678** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 33 (actual)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Sirolimus 2mg

## Key facts

- **NCT ID:** NCT03304678
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2025-03-09
- **Final completion:** 2025-03-14
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03304678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03304678, "Discovery of Sirolimus Sensitive Biomarkers in Blood". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03304678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*